Refrences 

1. Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide: Literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
2. Hsieh, M.-J., Liu, H.-T., Wang, C.-N., Huang, H.-Y., Lin, Y., Ko, Y.-S., Wang, J.-S., Chang, V. H.-S., & Pang, J.-H. S. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin), 95(3), 323-333. https://doi.org/10.1007/s00109-016-1488-y
3. Jung, Y. H., Lee, J. G., Park, S. K., & Lee, H. (2022). The anti-nociceptive effect of BPC-157 on the incisional pain model. Journal of Dental Anesthesia and Pain Medicine, 22(5), 375–383. https://doi.org/10.17245/jdapm.2022.22.5.375
4. Arborelius, M., Andersson, S. (2023). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Review of Mechanisms and Applications. Journal of Experimental Orthopaedics, 10(1), Article 12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313605/
5. U.S. Anti-Doping Agency. (n.d.). BPC-157: Experimental Peptide Prohibited. Retrieved from https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/?utm